Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective [0.03%]
从英国角度看或利万星治疗急性细菌性皮肤和皮肤结构感染的成本最小化分析
Daniela Zinzi,Ioanna Vlachaki,Edel Falla et al.
Daniela Zinzi et al.
Background: Early discharge (ED) from hospital and outpatient parenteral antibiotic therapy (OPAT) are effective approaches for the management of a range of infections, including acute bacterial skin and skin structure in...
Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above [0.03%]
PAM-13量表在匈牙利40岁以上人群中的验证研究
Zsombor Zrubka,Péter Vékás,Péter Németh et al.
Zsombor Zrubka et al.
Background: Patient activation comprises the skills, knowledge and motivation necessary for patients' effective contribution to their care. We adapted and validated the 13-item Patient Activation Measure (PAM-13) in the ...
One last effort. Are high out-of-pocket payments at the end of life a fatality? [0.03%]
最后一搏。临终期高昂的自费医疗费用不可避免吗？
Rosalind Bell-Aldeghi,Nicolas Sirven,Morgane Le Guern et al.
Rosalind Bell-Aldeghi et al.
Only few studies outside of the US have addressed the issue of out-of-pocket payments (OOP) at the end of life because of a lack of data. We use an exclusive dataset from a major French health insurance company (MGEN), including claim data,...
The impact of ambulatory care spending, continuity and processes of care on ambulatory care sensitive hospitalizations [0.03%]
门诊支出、连续性和医疗过程对可以通过门诊治疗的住院事件的影响
Wiebke Schuettig,Leonie Sundmacher
Wiebke Schuettig
Ambulatory care sensitive hospitalizations are widely considered as important measures of access to as well as quality and performance of primary care. In our study, we investigate the impact of spending, process quality and continuity of c...
Supply-side solutions targeting demand-side characteristics: causal effects of a chronic disease management program on adherence and health outcomes [0.03%]
针对需求端特征的供给侧解决方案：慢病管理项目对治疗依从性和健康结果的影响评估
Luke Connelly,Gianluca Fiorentini,Marica Iommi
Luke Connelly
We estimate the effects of a chronic disease management program (CDMP) which adapts various supply-side interventions to specific demand-side conditions (disease-staging) for patients with chronic kidney disease (CKD). Using a unique datase...
Defining minimum volume thresholds to increase quality of care: a new patient-oriented approach using mixed integer programming [0.03%]
定义最小业务量阈值以提高护理质量：使用混合整数编程的一种新的面向患者的方法
Justus F A Vogel,Max Barkhausen,Christoph M Pross et al.
Justus F A Vogel et al.
A positive relationship between treatment volume and outcome quality has been demonstrated in the literature and is thus evident for a variety of procedures. Consequently, policy makers have tried to translate this so-called volume-outcome ...
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations [0.03%]
CHEERS 2022 声明：卫生经济学评价报告的更新指南
Don Husereau,Michael Drummond,Federico Augustovski et al.
Don Husereau et al.
Health economic evaluations are comparative analyses of alternative courses of action in terms of their costs and consequences. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, published in 2013, was creat...
Does the abolition of copayment increase ambulatory care utilization?: a quasi-experimental study in Germany [0.03%]
免除共付费用是否增加了门诊利用率？德国的一项准实验研究
Mingming Xu,Benjamin Bittschi
Mingming Xu
Due to a problematic situation with public finances, Germany introduced a copayment scheme for ambulatory care visits in 2004. In 2012, Germany achieved a balanced budget, and copayment was abolished on the 1st of January 2013. This policy ...
Do we care about high-cost patients? Estimating the savings on health spending by integrated care [0.03%]
我们关注高医疗费用患者吗？综合护理节省医疗开支的估计效果分析
Karen Geurts,Marc Bruijnzeels,Erik Schokkaert
Karen Geurts
A recent integrated health care initiative in Belgium supports 12 regional pilot projects scattered across the country and representing 21% of the population. As in shared savings programs, part of the estimated savings in health spending a...
Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study [0.03%]
卡培他滨用于III期结直肠癌术后一年辅助化疗的经济学分析：JFMC37-0801研究的事先计划好成本效益分析
Hidetoshi Shibahara,Takeru Shiroiwa,Megumi Ishiguro et al.
Hidetoshi Shibahara et al.
Objectives: We evaluated the cost-effectiveness of a 12-month regimen of oral capecitabine versus a standard 6-month regimen as postoperative adjuvant chemotherapy for stage III colon cancer. ...